Checkpoint Therapeutics shares are trading higher after the company announced it reached alignment with the FDA on its on its biologics license application resubmission strategy for cosibelimab.
Portfolio Pulse from Benzinga Newsdesk
Checkpoint Therapeutics shares are trading higher after the company announced it reached alignment with the FDA on its biologics license application resubmission strategy for cosibelimab.
June 24, 2024 | 4:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Checkpoint Therapeutics shares are trading higher following the company's announcement of reaching alignment with the FDA on its biologics license application resubmission strategy for cosibelimab.
The alignment with the FDA on the resubmission strategy for cosibelimab is a significant regulatory milestone for Checkpoint Therapeutics. This development increases the likelihood of approval, which is a positive catalyst for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100